Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Bolt Biotherapeutics, Inc. - Common Stock
(NQ:
BOLT
)
5.420
+0.110 (+2.07%)
Streaming Delayed Price
Updated: 3:24 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Bolt Biotherapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 12, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
October 01, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
May 12, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
May 08, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody™ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
April 30, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
April 25, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
March 25, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
March 24, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics to Participate in Upcoming March Conferences
February 25, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
February 11, 2025
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 12, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
November 07, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bolt Biotherapeutics Announces Changes to its Board of Directors
September 04, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 03, 2024
From
The Schall Law Firm
Via
Business Wire
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
September 02, 2024
From
Rosen Law Firm
Via
Business Wire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
September 02, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 30, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
August 29, 2024
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Bolt Biotherapeutics to Participate in Upcoming September Conferences
August 28, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 20, 2024
From
Schall Law
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
August 17, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 16, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bolt Biotherapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
From
Bolt Biotherapeutics, Inc.
Via
GlobeNewswire
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 13, 2024
From
Schall Law
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 12, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
August 09, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CVS, Walgreens, SeaStar, and Bolt and Encourages Investors to Contact the Firm
August 06, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
